Appeals panel sits at the center of this dementia and brain health question.

In late March 2026, a UK appeals panel ordered the National Institute for Health and Care Excellence (NICE) to reconsider its rejection of two Alzheimer’s drugs: Leqembi and Kisunla. The panel found significant flaws in NICE’s original decision-making process and determined that the drugs deserve a fresh evaluation under new, more favorable cost-effectiveness thresholds. This marks a potential turning point for patients with early-stage Alzheimer’s disease in the UK, though it does not yet guarantee NHS approval.

The reconsideration will focus on overlooked factors including the economic value of unpaid caregiver work, improved estimates of infusion costs, and longer-term clinical data that may strengthen the case for these disease-modifying treatments. This article explains what triggered the appeals panel’s decision, why NICE originally rejected these drugs despite their clinical benefits, and what the reconsideration process means for UK patients, caregivers, and the NHS. We’ll examine the clinical evidence, the cost barriers that have blocked approval three times, and how newly considered factors like caregiver burden might shift the affordability calculation.

What Triggered the Appeals Panel to Order NICE’s Reconsideration?
Understanding the Clinical Evidence Behind Leqembi and Kisunla
The Cost Barrier That Led to Rejection—and May Persist
How Overlooked Caregiver Costs Could Change the Equation
What NICE Must Reassess—and Why It Matters
The Timeline and What Comes Next
Implications for UK Patients and Future Alzheimer’s Drug Approvals
Conclusion

What Triggered the Appeals Panel to Order NICE’s Reconsideration?

Both Leqembi (lecanemab, made by Eisai) and Kisunla (donanemab, made by Eli Lilly) had been rejected by NICE on June 19, 2025—their third rejection in a series of appeals. Rather than accept that final decision, the drug manufacturers appealed to an independent panel, arguing that NICE’s appraisal process contained procedural and substantive errors. The panel agreed. In March 2026, it found that NICE had failed to properly account for certain evidence and analytical approaches that should have factored into the decision. The appeals panel’s ruling was narrow but decisive: it identified four specific areas where NICE’s analysis fell short.

First, NICE had not adequately considered the unpaid care work performed by family members and spouses—a significant cost burden that the NHS doesn’t directly pay but patients and their families bear. Second, the panel found that NICE’s conclusions on how these drugs improve caregiver quality of life were based on incomplete evidence review. Third, the original appraisal underestimated the actual costs of administering intravenous infusions in NHS settings. Fourth, NICE’s analysis of long-term data was insufficient. Unlike a simple reversal, the appeals panel didn’t approve the drugs; instead, it required NICE to redo its assessment with these factors properly weighed.

What Triggered the Appeals Panel to Order NICE's Reconsideration?

Understanding the Clinical Evidence Behind Leqembi and Kisunla

Both Leqembi and Kisunla are monoclonal antibodies designed to target amyloid-beta, a protein that accumulates in the brains of Alzheimer’s disease patients. They are approved for people with mild cognitive impairment or mild dementia—early stages of disease—not for moderate or advanced Alzheimer’s. The clinical evidence is consistent: both drugs delay the progression from mild to moderate dementia by approximately 4 to 6 months. This is a meaningful benefit for patients and families facing a neurodegenerative condition with no cure, though it is also modest in scope.

The limitation here is important to understand: these drugs do not stop Alzheimer’s disease progression, they merely slow it. For a patient diagnosed at age 70, a 4 to 6-month delay might mean preserving independence and cognitive function for a few additional months—time that matters deeply to individuals and caregivers, but which does not address the underlying disease biology. Both drugs require regular intravenous infusions, which adds to the logistical burden and medical complexity. Additionally, both carry potential side effects related to amyloid-related imaging abnormalities (ARIA), including brain microhemorrhages and microinfarcts, which require monitoring through regular MRI scans.

The Cost Barrier That Led to Rejection—and May Persist

The fundamental reason NICE rejected Leqembi and Kisunla was cost-effectiveness. In the US market, Leqembi costs approximately $26,500 per year, while Kisunla costs approximately $32,000 per year. In the UK private market, a single-dose vial of Leqembi costs around £893. When NHS England analyzed the potential cost of providing both drugs to the population of UK patients with mild cognitive impairment or mild dementia, the estimate ranged from £500 million to £1 billion annually—a substantial expense for a healthcare system with fixed budgets.

NICE applies a cost-effectiveness threshold, typically evaluating whether the clinical benefit justifies the cost in terms of quality-adjusted life years (QALYs) gained per pound spent. In its original rejection, NICE determined that the modest 4 to 6-month delay in progression did not represent good value for the NHS at the proposed price. However, the appeals panel ruled that NICE must reconsider using new, higher cost-effectiveness thresholds. This is crucial: higher thresholds mean NICE is willing to accept a higher cost per QALY gained, which could shift the affordability calculation in favor of these drugs. This doesn’t guarantee approval, but it does create a pathway where the same clinical evidence might now meet the threshold for funding.

The Cost Barrier That Led to Rejection—and May Persist

How Overlooked Caregiver Costs Could Change the Equation

One of the panel’s key findings was that NICE had not adequately factored in the substantial costs borne by family caregivers. When an Alzheimer’s patient lives longer in the mild to moderate stage, their family caregiver—often a spouse, adult child, or close relative—continues to provide supervision, assistance with activities of daily living, emotional support, and medical coordination. This unpaid care work represents real economic value, even though families don’t receive payment for it.

By delaying progression to more severe dementia by several months, Leqembi and Kisunla extend the period during which a patient may require less intensive care. This reduces the caregiver burden and allows families to postpone the move to residential care facilities, which are far more expensive for the NHS than community-based care with family support. The appeals panel argued that NICE should have incorporated these caregiver quality-of-life improvements and care cost savings into its economic model. The reconsideration will likely include a more sophisticated analysis of how these drugs affect not just patient outcomes, but the sustainability of family-based care arrangements.

What NICE Must Reassess—and Why It Matters

NICE’s reconsideration is not a rubber stamp approval; it is a structured re-evaluation with specific areas of focus. The panel identified that NICE must revisit its assumptions about infusion costs in NHS settings. Administering intravenous drugs in hospitals, clinics, or home-care settings involves nurse time, equipment, and infrastructure costs that may have been underestimated in the original appraisal. A more accurate assessment of these operational costs could affect the overall cost-effectiveness calculation. Additionally, the panel found that NICE’s review of long-term clinical data was incomplete.

Since the original approval of these drugs by regulatory authorities, more real-world evidence may have accumulated showing how they perform in actual clinical practice, not just in controlled trials. The reconsideration will include this newer data. Importantly, the appeals panel indicated that higher cost-effectiveness thresholds will apply—potentially ranging from £30,000 to £50,000 or more per QALY gained, compared to the traditional NICE threshold of £20,000 to £30,000 per QALY. This higher threshold is significant because it means the economic hurdle for approval is lower. However, a limitation remains: even with higher thresholds and better data, NICE could still conclude that the drugs don’t represent sufficient value.

What NICE Must Reassess—and Why It Matters

The Timeline and What Comes Next

As of late March 2026, NICE has not yet announced specific dates for the committee meetings that will carry out the reconsideration. The process will involve independent assessment groups reviewing the new evidence, manufacturers submitting updated economic models incorporating caregiver costs and revised infusion cost estimates, and NICE committees deliberating on the revised appraisal. Historically, similar reassessments take several months, so a decision could come in mid-2026, though timelines are uncertain.

During this interim period, patients in the UK who wish to access Leqembi or Kisunla must do so through private healthcare or clinical trials. Some may qualify for early-access schemes if the manufacturers offer them. The reconsideration provides hope for potential NHS access, but it also means that patients cannot rely on funded availability in the immediate term.

Implications for UK Patients and Future Alzheimer’s Drug Approvals

The appeals panel’s decision signals that NICE’s decision-making process is subject to scrutiny and correction—a safeguard that protects both the integrity of health technology assessment and the interests of patients. The specific focus on caregiver costs and quality of life suggests that future evaluations of Alzheimer’s and other chronic disease treatments will need to weigh not just direct medical benefits, but the broader social and economic impacts on families.

The outcome of NICE’s reconsideration will influence how pharmaceutical companies price other Alzheimer’s drugs and how regulatory bodies in other countries evaluate these treatments. If NICE reverses course and approves Leqembi and Kisunla, it would reinforce that robust appeals processes can correct initial decisions. If NICE again rejects them despite the panel’s concerns, it would demonstrate that even with revised cost-effectiveness thresholds, the affordability challenge remains insurmountable at current prices.

Conclusion

The appeals panel’s March 2026 decision to require NICE to reconsider Leqembi and Kisunla represents a significant procedural victory for patients and manufacturers, though it is not yet a clinical or commercial victory. The panel identified genuine flaws in NICE’s original analysis, particularly regarding caregiver burden and operational costs, and mandated a reassessment under more favorable cost-effectiveness thresholds. These drugs remain among the first disease-modifying treatments for early Alzheimer’s disease with evidence of slowing progression, and the reconsideration offers a pathway for them to potentially benefit UK patients through NHS funding.

For people with mild cognitive impairment or mild dementia and their families, the coming months will be critical. Those interested in accessing these drugs should discuss options with their healthcare provider, including the possibility of private treatment, clinical trial participation, or manufacturer-sponsored access programs while the NHS appraisal proceeds. The reconsideration is not guaranteed to result in approval, but it does mean the case for these drugs will be heard again—with a fuller understanding of what they offer to patients and the caregivers who support them.